Search

Educational Travel Grants

EHA wants to facilitate participation in the Annual Congress for hematologists, researchers and practitioners from lower and middle-income countries.

Read more

Meeting Program

All times are in GMT-3, local time in Brazil.

Read more

Chairs and Members

ChairJane Apperley

Co-chairAndreas Hochhaus

Executive Board members (2021–2027 term)
Prof Nicholas CP Cross, University of Southampton (UK)
Prof Oliver Hantschel, University of Marburg (Germany)
Dr Delphine Rea, University of Paris (France)
Dr Katerina Machova Polakova, Institute of Hematology and Blood Transfusion, Prague; Charles University (Czech Republic)
Prof…

Read more

Chairs and Members

Chair (2017-ongoing)Oliver A. Cornely—University Hospital Cologne, Cologne (Germany)

Co-chair (2023-ongoing)Livio Pagano—Fondazione Policlinico A.

Read more

I4MDS consortium: advancing MDS treatment and understanding

The role of the immune system in the pathophysiology of Myelodysplastic Neoplasms (MDS) is firmly established. However, routine immune monitoring for these patients is still not a common practice.

Read more

Registration & accommodation

Registration is now closed

Individual registrationHybrid registration includes:

In-person access to the scientific and educational sessions of the meeting
Access to the virtual platform
Meeting materials
Coffee/tea breaks on February 9-11, 2023 and lunches on February 10 & 11
Access to the Welcome Reception
Access to the…

Read more

I would like to be an EHA Member

Our members come from all corners of the world – from a University Hospitals in India to research companies in Germany.

Read more

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more